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ABSTRACT
Objectives. To evaluate the predictive ability of the previously published NORRISK 2 cardiovascular risk
model in Norwegian-born and immigrants born in South Asia living in Norway, and to add information
about diabetes and ethnicity in an updated model for South Asians and diabetics (NORRISK 2-SADia).
Design. We included participants (30–74 years) born in Norway (n¼ 13,885) or South Asia (n¼ 1942)
from health surveys conducted in Oslo 2000–2003. Cardiovascular disease (CVD) risk factor information
including self-reported diabetes was linked with information on subsequent acute myocardial infarc-
tion (AMI) and acute cerebral stroke in hospital and mortality registry data throughout 2014 from the
nationwide CVDNOR project. We developed an updated model using Cox regression with diabetes
and South Asian ethnicity as additional predictors. We assessed model performance by Harrell’s C and
calibration plots. Results. The NORRISK 2 model underestimated the risk in South Asians in all quintiles
of predicted risk. The mean predicted 13-year risk by the NORRISK 2 model was 3.9% (95% CI 3.7–4.2)
versus observed 7.3% (95% CI 5.9–9.1) in South Asian men and 1.1% (95% CI 1.0–1.2) versus 2.7%
(95% CI 1.7–4.2) observed risk in South Asian women. The mean predictions from the NORRISK 2-
SADia model were 7.2% (95% CI 6.7–7.6) in South Asian men and 2.7% (95% CI 2.4–3.0) in South
Asian women. Conclusions. The NORRISK 2-SADia model improved predictions of CVD substantially in
South Asians, whose risks were underestimated by the NORRISK 2 model. The NORRISK 2-SADia model
may facilitate more intense preventive measures in this high-risk population.
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International guidelines for prevention of cardiovascular dis-
ease (CVD) recommend the estimation of an individual’s
total risk of CVD to inform treatment decisions [1,2]. The
recent Norwegian guidelines recommend risk calculation by
the NORRISK 2 model, which predicts an individual’s 10-
year risk of incident fatal or non-fatal acute myocardial
infarction (AMI) or cerebral stroke [3,4]. The NORRISK 2
model has not been validated among immigrants in
Norway. Migrants originating from South Asia (India,
Pakistan, Sri Lanka, Bangladesh, Nepal and Bhutan) have
higher risk of CVD compared to other ethnic groups in sev-
eral countries, including the United Kingdom (UK),
Denmark, Sweden, Italy, the United States, New Zealand
and Norway [5–11]. In 2019, immigrants and Norwegian-
born to immigrant parents with a country background from
South Asia living in Norway counted 75,227 individuals
[12]. We previously reported that immigrants from South
Asia have an increased risk of CVD compared to ethnic
Norwegians after adjustment for traditional risk factors [13].
Norwegian guidelines recommend adding a factor of 1.5
to the predicted risk score in South Asians to account for
possible underestimation of risk [4]. The prevalence of type
2 diabetes is considerably higher in immigrants from South
Asia than in the general Norwegian population [13,14].
Furthermore, South Asian migrants living in high-income
countries are diagnosed with diabetes at a younger age than
Europeans [15]. The NORRISK 2 model did not include
diabetes because there are separate guidelines for CVD pre-
vention in diabetics advising preventive medication (statins)
to all diabetic patients, provided LDL-cholesterol is
>2.5mmol/L and age >40 years [4]. However, when esti-
mating the burden of CVD in a given population (i.e. a city
or community) the exclusion of diabetes and ethnicity
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would give invalid and underestimated cardiovascular risk
estimates in South Asians and people with diabetes. The
purpose of this study was to evaluate the NORRISK 2 model
in men and women born in Norway and South Asia, and to
include South Asian ethnicity and diabetes as additional
predictors in an updated model called NORRISK 2-SADia.
Materials and methods
Study population
We included participants from health examination surveys;
The Oslo Health Study (HUBRO), The Oslo Immigrant
Health Study (I-HUBRO) and the Romsås in Motion Study
(MoRo II) (N¼ 26,884), all conducted in Oslo during
2000–2003 and part of Cohort of Norway (CONOR) [16].
Participation rates were 40–48%. All surveys followed stand-
ard data collection procedures. Self-reported questionnaires
included questions about self-reported health and disease,
family history of disease, medication use and lifestyle [16].
Participants underwent a clinical examination and non-fast-
ing blood samples were analyzed for serum lipids by stand-
ard methods [16]. Systolic blood pressure (SBP) was
measured using an automatic device. Further details on data
collection are given elsewhere [16].
We included participants aged 30–74 years at examin-
ation. The final study population included 7574 women and
6311 men born in Norway, and 795 women and 1147 men
born in South Asia. See Appendix Figure 1 in supplemen-
tary materials for details. About 3.9% of South Asians and
2.7% of Norwegians emigrated during follow-up.
Participants signed a written informed consent. The
Regional Committee for Medical and Health Research
Ethics approved the study.
Cardiovascular outcomes
An endpoint was defined as the first occurrence of hospital-
ization with AMI (ICD10 I21-22) or acute cerebral stroke
(ICD10 I60-61, I63-I64 except I63.6) as main or secondary
diagnosis or death with CHD (ICD10 I20-25) or cerebral
stroke as the underlying cause. The CVDNOR project
includes hospitalizations retrieved from patient administra-
tive systems during 1994–2009, and from the Norwegian
Patient Registry from 2008 to 2014 [17,18]. Fatal events
were retrieved from the Cause of Death Registry. Follow-up
time was calculated from the CONOR participation date
until date of hospitalization, death or end of follow-up (31
December 2014), whichever occurred first.
Statistical analyses
The NORRISK 2 model [3] predicts 10-year risk of CVD
based on continuous (age, serum total cholesterol and SBP
(per 10mmHg)) and categorical risk factors (low high-dens-
ity lipoprotein (HDL)-cholesterol (<1.3mmol/L in women,
<1.0mmol/L in men), daily smoking, current use of antihy-
pertensive medication and family history (first-degree family
member) of CHD before the age of 60). The NORRISK 2
model predicts 10-year risk by the Fine and Gray competing
risk model [19]. In the current study, we evaluate 13-year
risk because of few cases in the South Asian group. In the
13-year risk calculation, we used the sub-distribution haz-
ards at 13 years instead of 10 years. We calculated the
observed cumulative 13-year incidence of CVD using life
table methods.
We validated the model by Harrell’s C and calibration
plots based on observed cumulative 13-year risk within
quintiles of predicted risk by NORRISK 2.
The NORRISK 2 model was intended for individuals
aged 40–79 years. Due to few participants at higher ages in
the South Asian group, we included individuals aged
30–74 years. Competing risk is small in these age groups;
we, therefore, used Cox regression to develop an updated
NORRISK 2 model (NORRISK 2-SADia) including diabetes
and South Asian region of birth in addition to the
NORRISK 2 predictors.
Results
Norwegian-born participants were on average 3 years older
than South Asians, had higher mean levels of SBP and a
higher proportion reported family history of AMI or stroke
(Table 1). However, the proportion reporting diabetes was
5–8 times higher in South Asians who also had considerably
lower HDL-cholesterol. Only 1.6% of South Asian women
reported daily smoking.
During 13 years of follow-up, we observed 621 endpoints
(Table 2). The observed cumulative incidence of CVD
ranged from 2.3% in Norwegian women to 7.3% in South
Asian men. Predicted 13-year risk by NORRISK 2 was con-
siderably higher in Norwegians compared to South Asians.
NORRISK 2 underestimated 13-year risk in South Asian
men and women, with and without known diabetes and in
Norwegian born men with diabetes (Table 2). NORRISK 2
underestimated risk in all quintiles of predicted risk in
South Asians, most pronounced in the two highest quintiles
(Figure 1 and Appendix Table 1 in supplementary materi-
als). The discriminative ability of NORRISK 2 was good in
both sexes and ethnic groups with Harrell’s C estimates
from 0.79 to 0.81 (Appendix Table 2 in supplemen-
tary materials).
We developed a new sex-specific model, NORRISK 2-
SADia, adding diabetes and ethnicity to the NORRISK 2
predictors (Table 3, Appendix Table 3 in supplementary
materials). Use of anti-hypertensive medications, low HDL-
cholesterol and family history of CHD were not significant
predictors in women and included as predictors in the final
model for men only. A model with all predictors included
also for women is shown in Supplementary materials
(Appendix Table 4). The adjusted hazard ratios (HRs) for
CVD events in South Asians versus Norwegians in the
NORRISK 2-SADia model were 1.7 in men and 2.7 in
women, whereas the HR for diabetes was 2.0 in both sexes
(Table 3). The mean 13-year risk score based on the
updated model was close to the observed cumulative risk,
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for both sexes, both ethnic groups and regardless of known
diabetes status (Table 2). NORRISK 2 multiplied by 1.5, as
recommended in Norwegian guidelines, gave similar pre-
dicted risk estimates as NORRISK 2-SADia among South
Asian men without diabetes, but not in South Asian men
with diabetes nor in South Asian women.
The calibration was good (Appendix Table 1 in supple-
mentary materials and Figure 2). The discriminative ability
was similar for NORRISK 2-SADia and NORRISK 2
(Appendix Table 1 in supplementary materials).
Appendix Table 5 in supplementary materials shows risk
classifications in men and women without known diabetes,
according to the Norwegian guidelines [4]. For Norwegian-
born men and women, there is a change towards lower risk
categories with NORRISK 2-SADia compared to NORRISK
2. Men and women born in South-Asia have a higher esti-
mated risk by NORRISK 2-SADia when compared to the
original model. However, NORRISK 2 multiplied by 1.5 and
NORRISK 2-SADia gave similar percentages in the high-risk
category for South-Asian men. The risk was low in South-
Asian women according to both models.
Discussion
NORRISK 2 underestimated the risk of incident AMI and
stroke in South Asian men and women living in Norway
with about a twofold difference between observed and pre-
dicted risk. As expected, the NORRISK 2 model also
Table 1. Baseline characteristics of participants born in Norway and in South Asia. Participants free of prior CVD.
Men Women
Norwegian South Asian Norwegian South Asian
N 6311 1147 7574 795
Age (years), mean (SD) 44 (11.5) 41.3 (7.8) 43.8 (10.8) 40.4 (8.1)
Age range (years) 30–74 30–67.8 30–74.9 30–65.5
Serum total cholesterol (mmol/L), (mean (SD) 5.61 (1.04) 5.48 (0.97) 5.40 (1.01) 5.02 (0.89)
HDL-cholesterol (mmol/L), mean (SD) 1.31 (0.34) 1.08 (0.25) 1.62 (0.40) 1.23 (0.29)
Low HDL-cholesterol (men < 1mmol/L, women < 1.3mmol/L) (%) 15.9 41.9 20.9 63.5
Systolic blood pressure (mm Hg), mean (SD) 132.8 (14.4) 126.8 (12.9) 124.4 (15.2) 120.5 (14.7)
Diastolic blood pressure (mm Hg), mean (SD) 77.8 (10.8) 77.0 (9.8) 71.7 (10.1) 70.8 (9.7)
Hypertensiona (%) 31.3 22.1 19.0 16.9
Diabetes (%) 1.7 8.5 1.4 11.2
Former smokers (%) 27.8 15.8 26.0 1.6
Current smokers (%) 26.0 24.5 31.4 1.6
Family history of AMI before age 60 (%): 12.0 7.0 12.8 8.2
One family member (%) 11.3 6.3 11.8 6.9
At least two family members (%) 0.7 0.7 1.0 1.3
Family history of stroke (%) 11.0 2.7 13.6 4.7
Antihypertensive treatment (%) 7.1 7.6 5.8 8.7
Lipid-lowering treatment (%) 4.4 6.2 2.9 6.7
Endpoints: n (%) 391 (6.2) 80 (7.0) 188 (2.5) 21 (2.6)
AMI/death from CHD: n (%) 235 (3.7) 60 (5.2) 87 (1.2) 16 (2.0)
Acute cerebral stroke : n (%) 175 (2.8) 27 (2.4) 109 (1.4) 5 (0.6)
Follow-up time (years), mean (SD) 13.2 (2.3) 12.4 (2.1) 13.4 (1.7) 12.9 (1.3)
SD: standard deviation; HDL: high-density lipoprotein; AMI: acute myocardial infarction; CHD: coronary heart disease.
aHypertension: systolic blood pressure >¼140mmHg or diastolic blood pressure >¼90mmHg or using blood pressure medication.
Table 2. Observed and predicted cumulative 13-year risk of CVD according to NORRISK2, original and updated (NORRISK2-SADia).
Men Women
Norwegian South Asian Norwegian South Asian
Total
N 6311 1147 7574 795
No. of events 355 77 170 19
Observed cumulative incidence, percent (95% CI) 5.8 (5.2–6.4) 7.3 (5.9–9.1) 2.3(2.0–2.7) 2.7 (1.7–4.2)
Predicted NORRISK2, percent (95% CI) 6.3 (6.2–6.5) 3.9 (3.7–4.2) 2.7 (2.6–2.8) 1.1 (1.0–1.2)
Predicted NORRISK21.5, percent (95% CI) – 5.9 (5.5–6.3) – 1.7 (1.5–1.9)
Predicted NORRISK2-SADia, percent (95% CI) 5.9 (5.8–6.1) 7.2 (6.7–7.6) 2.4 (2.3–2.4) 2.7 (2.4–3.0)
Not known diabetes
N 6201 1050 7469 706
No. of events 325 62 165 13
Observed cumulative incidence, percent (95% CI) 5.4 (4.8–6.0) 6.5 (5.0–8.3) 2.3 (2.0–2.6) 2.1 (1.2–3.7)
Predicted NORRISK2, percent (95% CI) 6.2 (6.0–6.4) 3.7 (3.4–3.9) 2.7 (2.6–2.8) 1.0 (0.9–1.1)
Predicted NORRISK21.5, percent (95% CI) – 5.5 (5.1–5.9) – 1.5 (1.3–1.7)
Predicted NORRISK2-SADia, percent (95% CI) 5.6 (5.5–5.8) 5.9 (5.6–6.3) 2.3 (2.2–2.4) 2.1 (1.9–2.3)
With known diabetes
N 110 97 105 89
No. of events 30 15 5 6
Observed cumulative incidence, percent(95% CI) 29.6 (21.6–39.7) 16.5 (10.2–26.1) 5.0 (2.1–11.7) 6.8 (3.1–14.6)
Predicted NORRISK2, percent (95% CI) 13.3 (11.4–15.1) 6.9 (5.6–8.2) 5.7 (4.2–7.1) 2.1 (1.6–2.6)
Predicted NORRISK21.5, percent (95% CI) – 10.4 (8.5–12.4) – 3.1 (2.4–3.9)
Predicted NORRISK2-SADia, percent (95% CI) 22.8 (19.9–25.8) 20.3 (17.3–23.4) 7.1 (5.5–8.7) 7.4 (5.8–9.0)
CI: confidence interval.
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underestimated the risk in Norwegian-born men with dia-
betes. We, therefore, updated the NORRISK 2 model with
information about diabetes and South Asian ethnicity. The
updated NORRISK 2-SADia model may be used to predict
CVD risk in both South Asians and Norwegians in Norway
with and without diabetes. However, the use of such algo-
rithms is not recommended to make individual treatment
decisions in patients with diabetes, who are better evaluated
through separate diabetes guidelines [20]. We present details
of our new risk equation that enable the calculation of 10-
and 13-year predicted cardiovascular NORRISK 2-SADia
risk, or external validation of the model.
South Asians worldwide have an increased risk of CVD,
particularly CHD, compared with other ethnic groups
[5–11,21]. In a previous Norway-New Zealand collaborative
study, we found that South Asians in both countries had a
higher risk of CVD than people of European origin after
adjustment for SBP, TC/HDL-cholesterol ratio, smoking and
diabetes [13]. Despite a high awareness of the increased car-
diovascular risk in South Asians, few cardiovascular predic-
tion models have been validated in South Asian populations
[22]. As far as we know, only two studies have validated
cardiovascular prediction models in South Asians reporting
performance measures of both discrimination and calibra-
tion, one in the UK and our validation of the Framingham
cardiovascular risk model among Indians and Europeans in
New Zealand [23,24]. Validation of prognostic models is
essential as the consequence of using models with poor per-
formance could be either overtreatment of healthy individu-
als or undertreatment of high-risk individuals.
To account for the excess risk of CVD in South Asians,
different adjustment methods have been recommended to
lower the thresholds of existing risk scores in South Asians
[25–27]. The Norwegian guidelines recommend to multiply
the NORRISK 2 score by 1.5 in South Asian individuals [4],
similar to the previous UK recommendation of adding a
factor of 1.4 to the Framingham risk score for South Asian
men [27]. A validation study from the UK found that
Framingham multiplied by 1.4 predicted the risk reasonably
well in South Asian men [23]. The Framingham model
(without any adjustments) underestimated the risk in South
Asian women [23]. The European Society of Cardiology
(ESC) also suggests a correction factor of 1.4 when using
the European SCORE model to assess CVD risk among
first-generation immigrants from South Asia [1]. However,
according to the ESC guidelines, this should be interpreted
with caution as the underlying evidence is somewhat lim-
ited, and ethnicity-specific risk equations could be consid-
ered. The updated cardiovascular risk model for the UK,
QRISK3, exists in different versions [28]. One of the com-
prehensive QRISK3 versions (Model B with 21 predictors)
was validated in Indians, Pakistanis and Bangladeshis by the
model developers, and showed good performance according
to the D statistics, R2 and Harrell’s C [28].
Type 2 diabetes is an important factor for the high car-
diovascular risk in South Asians [13,29], and models that do
not take diabetes or South Asian ethnicity into account
might underestimate their risk. Both the NORRISK 2 and
NORRISK 2-SADia models discriminated well with similar
Harrell’s C-values. However, c-statistics are insensitive meas-
ures for model selection [30]. The calibration showed that
our NORRISK 2-SADia model improved risk prediction in
South Asians compared to NORRISK 2. However, we found
similar predicted risk estimates from NORRISK 2-SADia
and the NORRISK 2 model multiplied with 1.5 in South
Asian men without diabetes (Table 2). This conforms to
similar percentages categorized as being at high risk for
South Asians without diabetes according to these two mod-
els (Appendix Table 5 in supplementary materials), suggest-
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Figure 1. Calibration plots showing observed minus predicted 13-year risk for the previously published NORRISK 2 model.
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group. To test if NORRISK 2-SADia is generalizable to
other related populations, external validation is
required [31].
The number of endpoints was small among women.
Thus, although anti-hypertensive medications, low HDL-
cholesterol and family history of CHD did not prove to be
significant predictors for CVD among women in our data,
we still consider these variables to be important risk factors
for both men and women.
Other risk factors not considered here could possibly also
improve risk prediction for South Asians (in Norway).
However, too many predictors in a model could result in a
model more difficult to implement in clinical practice. We
have included the classical CVD risk factors and few end-
points preclude inclusion of many risk factors, especially
in women.
Strengths and limitations
A strength of this study is the population-based study
design and the inclusion of the major cardiovascular risk
factors in the model.
Table 3. The CVD risk model NORRISK 2-SADia, with inclusion of diabetes (yes/no) and region of birth (South Asia versus Norway) for pre-
diction of 10- and 13-year risk of acute cerebral stroke or acute myocardial infarction in men and women born in Norway or South-Asia.
Men (N¼ 7458, Women (N¼ 8369,
endpoints¼ 471) endpoints¼ 209)
Covariate HR 95% CI HR 95% CI
Age-40 1.08 1.07 1.09 1.09 1.07 1.11
Systolic blood pressure-120 (per 10mmHg) 1.15 1.09 1.21 1.18 1.09 1.27
Serum total cholesterol  4 (per 1mmol/L) 1.24 1.13 1.35 1.24 1.08 1.42
Daily smoking (yes/no) 2.04 1.52 2.72 2.69 2.02 3.57
Antihypertensives (yes/no) 1.40 1.09 1.79 – – –
Low HDL-cholesterol (yes/no) 1.63 1.32 2.02 – – –
Family history of CHD: one family member 1.26 0.96 1.65 – – –
Family history of CHD: at least two family members 2.42 1.36 4.31 – – –
Region of birth (South Asia versus Norway) 1.68 1.29 2.20 2.67 1.61 4.43
Diabetes (yes/no) 2.11 1.52 2.94 2.05 1.15 3.65
Daily smoking X (Age-40) 0.98 0.96 1.00 – – –
S0(10) 0.99275 – – 0.99746 – –
S0(13) 0.98902 – – 0.99608 – –
HR: Hazard ratio; CI: confidence interval; HDL: high-density lipoprotein; CHD: coronary heart disease
S0(10) and S0(13) are estimated baseline survivor functions at 10 and 13 years of follow-up.
10-year risk is calculated by 1-S0(10
) exp(Z*b) ¼ 1-S0(10) exp(Zln(HR)).
13-year risk is calculated by 1-S0(13)
exp(Z*b) ¼ 1-S0(13) exp(Zln(HR)).
The baseline survivor function is the survival at age ¼ 40, systolic blood pressure ¼ 120, serum total cholesterol ¼ 4, daily smoking ¼ 0,
other covariates ¼ 0.
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Figure 2. Calibration plots showing observed minus predicted 13-year risk for the updated NORRISK 2-SADia model.
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Cardiovascular risk prediction scores have different defi-
nitions of endpoints, which makes it difficult to compare
risk scores. A strength of the NORRISK 2 model compared
to the European SCORE model and the previous Norwegian
model (NORRISK) is the inclusion of both non-fatal and
fatal events. Non-fatal events are especially important to
address owing to the substantial decline in cardiovascular
mortality in Norway since the 1970s. The acute endpoints of
the NORRISK 2 model is also a strength as the ICD-coding
of AMI and acute stroke in administrative databases has
been found to be more reliable than less acute endpoints
such as angina, heart failure and peripheral arterial disease
[32–34]. We, therefore, believe coding of acute cardiovascu-
lar events to be of acceptable validity.
Diabetes information was self-reported. A previous study
based on data from two Oslo health studies (one is included
herein) showed that among South Asian diabetic men, about
50% had undiagnosed diabetes [14]. Undiagnosed diabetes
may have contributed to the observed high risk in South
Asians without known diabetes.
One limitation is the low participation rates (40–48%),
which increases the possibility of selection bias. Usually,
men and women who participate in health surveys are
healthier than non-participating men and women. If the
self-selection mechanisms were different for the different
ethnic groups, it could influence the ethnic comparisons in
this study. However, the ethnic differences in risk of CVD
in this paper correspond to ethnic differences in risk of
CVD that we found in a previous study where self-selection
was not a problem [11].
Another limitation is that we studied South Asians from
several countries combined despite within-group heterogen-
eity regarding CVD. We previously found that the standar-
dized AMI event rate per 100,000 person-years in Pakistani
men were 978 (95% CI 894–1061) versus 514 (95% CI
411–616) in Indian men [11]. Thus, it is possible that the
new risk score does not improve risk prediction equally well
for all South Asian subgroups. Also, excess risk may be
influenced by environmental factors and change over time.
Unfortunately, we did not have the information available to
distinguish between South Asian subgroups. Based on the
original health surveys, we have estimated that approxi-
mately 50% of the South Asian group are Sri Lankans and
35% are Pakistanis in our study [13].
Immigrants from Former Yugoslavia, the Middle East
and Central Asia also have increased cardiovascular risk
compared to Norwegian-born and may need more precise
risk prediction tools [11]. We did not have sufficient data to
study these ethnic groups, but it should be a future research
objective to validate the NORRISK 2 model among other
immigrant groups living in Norway.
In this article, we present an updated cardiovascular risk
model to predict the risk of CVD in immigrants from South
Asia living in Norway by including information about ethni-
city and diabetes. It is of great importance to evaluate and
improve the cardiovascular risk assessment tools in South
Asian populations given their high risk of CVD.
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